Haemophagocytic lymphohistiocytosis in an adult with postacute COVID-19 syndrome.
| Title: | Haemophagocytic lymphohistiocytosis in an adult with postacute COVID-19 syndrome. |
|---|---|
| Authors: | Wiseman D; Division of Internal Medicine, McGill University Health Centre, Montreal, Québec, Canada.; Lin J; Infectious Diseases and Immunity in Global Health Program, Research Institute of the McGill University Health Centre, Montréal, Québec, Canada.; Routy JP; Research Institute of the McGill University Health Centre, Montreal, Québec, Canada.; Division of Haematology, McGill University Health Centre, Montreal, Québec, Canada.; Samoukovic G; Division of Critical Care Medicine, McGill University Health Centre, Montreal, Québec, Canada gordan.samoukovic@mcgill.ca. |
| Source: | BMJ case reports [BMJ Case Rep] 2021 Sep 13; Vol. 14 (9). Date of Electronic Publication: 2021 Sep 13. |
| Publication Type: | Case Reports; Journal Article |
| Language: | English |
| Journal Info: | Publisher: BMJ Pub. Group Country of Publication: England NLM ID: 101526291 Publication Model: Electronic Cited Medium: Internet ISSN: 1757-790X (Electronic) Linking ISSN: 1757790X NLM ISO Abbreviation: BMJ Case Rep Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : BMJ Pub. Group |
| MeSH Terms: | Lymphohistiocytosis, Hemophagocytic*/complications ; Lymphohistiocytosis, Hemophagocytic*/diagnosis ; Lymphohistiocytosis, Hemophagocytic*/drug therapy ; COVID-19*; Etoposide/therapeutic use ; Adult ; Humans ; SARS-CoV-2 |
| Abstract: | Haemophagocytic lymphohistiocytosis (HLH) causing multiorgan failure has been reported as an acute clinical presentation of COVID-19. However, the literature surrounding HLH in the context of a postacute COVID-19 syndrome is limited. This report presents a case of a life-threatening HLH occurring 6 weeks after a pauci-symptomatic COVID-19 infection in a previously healthy adult. A bone marrow aspirate confirmed the HLH and the patient was successfully treated with dexamethasone and etoposide. To our knowledge, this is the first case of HLH occurring as a postacute COVID-19 syndrome following a pauci-symptomatic initial infection.; (© BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.) |
| Competing Interests: | Competing interests: None declared. |
| References: | Annu Rev Pathol. 2018 Jan 24;13:27-49. (PMID: 28934563); Blood. 2021 Apr 29;137(17):2337-2346. (PMID: 33512385); Clin Rheumatol. 2021 Apr;40(4):1233-1244. (PMID: 33389315); Cold Spring Harb Perspect Biol. 2018 Aug 1;10(8):. (PMID: 28778870); Pediatr Blood Cancer. 2007 Feb;48(2):124-31. (PMID: 16937360); Lancet. 2014 Apr 26;383(9927):1503-1516. (PMID: 24290661); MMWR Morb Mortal Wkly Rep. 2020 Oct 09;69(40):1450-1456. (PMID: 33031361); Int J Hematol. 2007 Jul;86(1):58-65. (PMID: 17675268); Circulation. 2008 Dec 16;118(25):2754-62. (PMID: 19106400); Curr Med Sci. 2021 Feb;41(1):39-45. (PMID: 33582903); Arthritis Rheumatol. 2014 Sep;66(9):2613-20. (PMID: 24782338); Nat Med. 2021 Apr;27(4):601-615. (PMID: 33753937); J Hematop. 2021 Apr 20;:1-5. (PMID: 33897909); Mayo Clin Proc. 2014 Apr;89(4):484-92. (PMID: 24581757); J Allergy Clin Immunol Pract. 2021 Sep;9(9):3293-3307.e6. (PMID: 34033983); Blood. 2019 Jun 6;133(23):2465-2477. (PMID: 30992265) |
| Contributed Indexing: | Keywords: COVID-19; adult intensive care; haematology (incl blood transfusion); malignant and benign haematology |
| Substance Nomenclature: | 6PLQ3CP4P3 (Etoposide) |
| Entry Date(s): | Date Created: 20210914 Date Completed: 20210915 Latest Revision: 20210925 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC8438920 |
| DOI: | 10.1136/bcr-2021-245031 |
| PMID: | 34518190 |
| Database: | MEDLINE |
Case Reports; Journal Article